Clinical study of Zhishen Yuanhu anticoagulant formula in prevention of venous thromboembolism in malignant tumor: a multicenter prospective randomized controlled clinical trial

uzhou People's Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Aged > 18 years;
•(2) There is no contraindication to anticoagulation therapy, and the expected survival is greater than 6 months.
•(3) Malignant tumors that occur in the pancreas, ovary, brain, stomach, gynecology, colon, lung, and hematology, and patients who have undergone surgery, radiotherapy and chemotherapy, or whose tumors are in advanced, advanced, and cachexia;
•(4) Normal coagulation function: PT 1216s, INR 0.81.5, APTT2436s, FIB24g/L;
•(5) Creatinine clearance rate> 20 ml/min;
•(6) Khorana scores are middle-high risk patients; (see appendix for Khorana scoring criteria);
•(7) Doppler ultrasonography before operation has no DVT;
•(8) The patient expressed informed consent and signed an informed consent form;
•(9) The test group ( Zhishen Yuanhu anticoagulant formula group) additional inclusion criteria: spleen and kidney yang deficiency, blood stasis type.

•(1) Known allergy to low molecular weight heparin sodium, leech, Yuanhu or Codonopsis;
•(2) Those with severe vascular sclerosis;
•(3) Those suffering from phlebitis of the lower extremities;
•(4) Patients with lower limb edema or pulmonary edema caused by congestive heart failure;
•(5) People with recent coagulation dysfunction or active bleeding from important organs;
•(6) Those with open wounds or skin infections on the skin of the lower limbs;
•(7) The test group (Zhishen Yuanhu anticoagulant formula group) additional exclusion criteria: damp-heat type (corresponding to thrombosis, acute phase), heterologous protein allergy, yellow and thick tongue coating.

发起方

uzhou People's Hospital